Evidence map›Paper›PMID 32413317›Full record

ReviewTrends in cell biology2020

Emerging Mechanisms and Disease Relevance of Ferroptosis.

Brent R Stockwell, Xuejun Jiang, Wei Gu

Open access · greenAbstract readReview
In one paragraph

Review in Trends in cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 626 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
626citing papers in PubMed, 3 pooled it
82.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

626 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,064 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Ferroptosis in kidney disease.Nature reviews. Nephrology · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

566 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Brent R StockwellDepartment of Biological Sciences and Department of Chemistry, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10027, USA. Electronic address: bstockwell@columbia.edu.
Xuejun JiangMemorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: jiangx@mskcc.org.
Wei GuInstitute for Cancer Genetics, Department of Pathology and Cell Biology, and Herbert Irving Comprehensive Cancer Center, College of Physicians & Surgeons, Columbia University, 1130 Nicholas Ave, New York, NY 10032, USA. Electronic address: wg8@cumc.columbia.edu.
Cancer Genetics (United States) · USColumbia University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Scientific ReagentsP01CA087497 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRIVES, CAROL · 2000 to 2021
$35.4M
Defining the functions and translational potential of ferroptosisR35CA209896 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI STOCKWELL, BRENT R. · 2016 to 2022
$6.5M
Regulation of p53 acetylation and deacetylation in tumorigenesis.R01CA085533 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2000 to 2021
$5.2M
Ferroptosis, Cellular Metabolism, and CancerR01CA204232 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JIANG, XUEJUN · 2017 to 2025
$4.1M
p53 acetylation in ferroptosis and tumor suppressionR01CA224272 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2018 to 2021
$1.5M
Development of ferroptosis inhibitors for Huntington DiseaseR61NS109407 · NINDS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI STOCKWELL, BRENT R. · 2019 to 2019
$400k
NCI NIH HHS P01 CA087497NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA085533NCI NIH HHS R01 CA204232NCI NIH HHS R01 CA224272NCI NIH HHS R35 CA209896NINDS NIH HHS R61 NS109407
6 · The paper itself

Abstract

Cell death is an essential feature of development in multicellular organisms, a critical driver of degenerative diseases, and can be harnessed for treating some cancers. Understanding the mechanisms governing cell death is critical for addressing its role in disease. Similarly, metabolism is essential for normal energy and biomolecule production, and goes awry in many diseases. Metabolism and cell death are tightly linked in the phenomenon of ferroptosis, a form of regulated cell death driven by peroxidation of phospholipids. Glutathione peroxidase 4 (GPX4) uses glutathione to protect cells from ferroptosis by eliminating phospholipid peroxides. Recent data have revealed glutathione/GPX4-independent axes for suppressing ferroptosis, and insight into the regulation of iron and mitochondria in ferroptosis. Ferroptosis has recently been implicated in multiple diseases, and functions as a tumor suppression mechanism. Ferroptosis induction is a promising approach in treating several conditions, including neoplastic diseases. Here, we summarize these recent advances.

Indexed as

DiseaseFerroptosisAnimalsHumansIronLipid PeroxidesMetabolic Networks and PathwaysNeoplasmsIronLipid Peroxidesferroptosisironlipid peroxidationmetabolismubiquinone, cancer

Identifiers

PMID32413317
PMCPMC7230071
OpenAlexW3012782412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.